Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME
Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a new analysis of data from its Phase 3 (FAME) clinical trials for Iluvien, the company’s investigational intravitreal insert being studied for diabetic macular edema (DME), indicates that patient vision continues …
Read more on News-Medical-Net
Related posts:
- Ampio Pharmaceuticals Announces Initiation Of Phase II Clinical Trial Of Optina™
- Clinical trial for diabetic macular edema enrolling patients
- Tranzyme reports positive results from TZP-102 Phase 2 study in diabetic patients with gastroparesis
- Amylin Pharmaceuticals to Present New Data and Insights From the Company’s Diabetes Programs at ADA 2010
- Research Roundup: Whistleblowers, Spreading Best Practices, Medicare’s Growth-Limiting Strategy